Cover Image
市場調查報告書

慢性疼痛:開發中產品分析

Chronic Pain - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213102
出版日期 內容資訊 英文 335 Pages
訂單完成後即時交付
價格
Back to Top
慢性疼痛:開發中產品分析 Chronic Pain - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 335 Pages
簡介

慢性疼痛,是指就算成因的損傷和急性疼痛消散了,在該處仍然持續疼痛的異常過程,警報系統未遮斷的狀態。慢性疼痛,起因於初期外傷/損傷和感染疾病,也可能是持續疼痛的原因。有倦怠感,不眠,免疫系降低,功能障礙等症狀。治療中,包含止痛藥,神經區域/手術等。

本報告提供慢性疼痛的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

慢性疼痛概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8545IDB

Summary

Global Markets Direct's, 'Chronic Pain - Pipeline Review, H2 2016', provides an overview of the Chronic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Pain and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Pain
  • The report reviews pipeline therapeutics for Chronic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Chronic Pain therapeutics and enlists all their major and minor projects
  • The report assesses Chronic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Chronic Pain

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chronic Pain
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chronic Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chronic Pain Overview
  • Therapeutics Development
    • Pipeline Products for Chronic Pain - Overview
    • Pipeline Products for Chronic Pain - Comparative Analysis
  • Chronic Pain - Therapeutics under Development by Companies
  • Chronic Pain - Therapeutics under Investigation by Universities/Institutes
  • Chronic Pain - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Chronic Pain - Products under Development by Companies
  • Chronic Pain - Products under Investigation by Universities/Institutes
  • Chronic Pain - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Acadia Pharmaceuticals Inc.
    • Adynxx, Inc.
    • Allergan Plc
    • Amorsa Therapeutics Inc.
    • arGEN-X BV
    • Asana BioSciences, LLC
    • AskAt Inc.
    • Astraea Therapeutics, LLC
    • Axsome Therapeutics, Inc.
    • BioDelivery Sciences International, Inc.
    • Biogen Inc
    • Bionomics Limited
    • Camurus AB
    • Cara Therapeutics, Inc.
    • Centrexion Therapeutics Corp
    • ChironWells GmbH
    • Collegium Pharmaceutical, Inc.
    • Crinetics Pharmaceuticals, Inc.
    • Cyclenium Pharma, Inc.
    • Cytogel Pharma, LLC
    • Daewoong Pharmaceutical Co., Ltd.
    • Daiichi Sankyo Company, Limited
    • Dompe Farmaceutici S.p.A.
    • Echo Pharmaceuticals B.V.
    • Egalet Corporation
    • Eli Lilly and Company
    • Elite Pharmaceuticals, Inc.
    • Glenmark Pharmaceuticals Ltd.
    • Grunenthal GmbH
    • Heron Therapeutics, Inc.
    • INSYS Therapeutics, Inc.
    • Johnson & Johnson
    • Kareus Therapeutics, SA
    • KPI Therapeutics, Inc.
    • Kymab Limited
    • Laboratorios Del Dr. Esteve S.A.
    • Lohocla Research Corporation
    • Lpath, Inc.
    • MD Biosciences GmbH
    • Merck & Co., Inc.
    • Moberg Pharma AB
    • Mundipharma International Ltd
    • Nanomerics Ltd
    • Nektar Therapeutics
    • Neura Therapeutik, LLC
    • Orion Oyj
    • Pacira Pharmaceuticals, Inc.
    • Pain Therapeutics, Inc.
    • PeriphaGen, Inc.
    • Pfizer Inc.
    • Phosphagenics Limited
    • Prismic Pharmaceuticals, Inc.
    • Purdue Pharma LP
    • Relmada Therapeutics, Inc.
    • Ribomic Inc.
    • Sea4Us
    • Shulov Innovative Science Ltd.
    • Synactix Pharmaceuticals, Inc.
    • Syntrix Biosystems, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Therapix Biosciences Ltd.
    • Trevena, Inc.
    • Voyager Therapeutics, Inc.
    • Yooyoung Pharmaceutical Co., Ltd.
    • Zynerba Pharmaceuticals, Inc.
  • Chronic Pain - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (celecoxib + tramadol hydrochloride) - Drug Profile
    • (hydrocodone bitartrate + palmidrol) - Drug Profile
    • (morphine sulfate + palmidrol) - Drug Profile
    • (naltrexone hydrochloride + oxycodone hydrochloride) SR - Drug Profile
    • (oxycodone hydrochloride + palmidrol) - Drug Profile
    • (palmidrol + pregabalin) - Drug Profile
    • A-200 - Drug Profile
    • AGN-XX - Drug Profile
    • AGN-YY - Drug Profile
    • AMS-520 - Drug Profile
    • ASN-008 - Drug Profile
    • AVLX-144 - Drug Profile
    • AXS-06 - Drug Profile
    • AYX-1 - Drug Profile
    • AYX-2 - Drug Profile
    • BBI-11008 - Drug Profile
    • bupivacaine - Drug Profile
    • bupivacaine hydrochloride - Drug Profile
    • buprenorphine hydrochloride - Drug Profile
    • buprenorphine hydrochloride depot - Drug Profile
    • buprenorphine hydrochloride ER - Drug Profile
    • buprenorphine hydrochloride long acting - Drug Profile
    • cebranopadol - Drug Profile
    • cetirizine hydrochloride + cromolyn sodium - Drug Profile
    • cetuximab - Drug Profile
    • CNTX-0290 - Drug Profile
    • CNV-3000164 - Drug Profile
    • CNV-3000223 - Drug Profile
    • CR-4056 - Drug Profile
    • CR-701 - Drug Profile
    • CRB-0089 - Drug Profile
    • Cyt-1010 - Drug Profile
    • dexmedetomidine hydrochloride - Drug Profile
    • DF-2593A - Drug Profile
    • difelikefalin - Drug Profile
    • dronabinol - Drug Profile
    • DS-1971 - Drug Profile
    • DWJ-208 - Drug Profile
    • ECP-1014 - Drug Profile
    • Egalet-003 - Drug Profile
    • fluticasone propionate - Drug Profile
    • FY-101C - Drug Profile
    • FY-103B - Drug Profile
    • GBR-900 - Drug Profile
    • Gene Therapy to Activate Mu Opioid Receptor for Chronic Pain - Drug Profile
    • grapiprant - Drug Profile
    • HPI-201 - Drug Profile
    • HS-731 - Drug Profile
    • hydrocodone bitartrate ER - Drug Profile
    • hydrocodone bitartrate ER - Drug Profile
    • hydrocodone bitartrate ER - Drug Profile
    • hydromorphone hydrochloride - Drug Profile
    • Kindolor - Drug Profile
    • KY-1017 - Drug Profile
    • L-779976 - Drug Profile
    • lacosamide - Drug Profile
    • LEVI-04 - Drug Profile
    • levorphanol tartrate ER - Drug Profile
    • Lpathomab - Drug Profile
    • MD-354 - Drug Profile
    • Monoclonal Antibodies for Chronic Pain - Drug Profile
    • Monoclonal Antibodies to Block Nav1.7 for Chronic Pain - Drug Profile
    • morphine sulfate ER - Drug Profile
    • MR-309 - Drug Profile
    • NET-END - Drug Profile
    • NKTR-181 - Drug Profile
    • NL-001 - Drug Profile
    • NL-002 - Drug Profile
    • NM-0127 - Drug Profile
    • Omnitram - Drug Profile
    • onabotulinumtoxin A - Drug Profile
    • OSX-300 - Drug Profile
    • OSX-300 Backups - Drug Profile
    • oxycodone hydrochloride ER - Drug Profile
    • oxycodone hydrochloride ER - Drug Profile
    • oxycodone hydrochloride ER - Drug Profile
    • oxymorphone hydrochloride - Drug Profile
    • oxymorphone hydrochloride ER - Drug Profile
    • PAC-CP - Drug Profile
    • palmidrol - Drug Profile
    • Peptide to Block Cav2.2 for CNS Disorders - Drug Profile
    • Peptides to Inhibit Ion Channel for Chronic Pain - Drug Profile
    • Peptides to Target TRPV1 for Pain and Itch - Drug Profile
    • PN-6047 - Drug Profile
    • PRC-062 - Drug Profile
    • Prostatic Acid Phosphatase - Drug Profile
    • PspTx-3 - Drug Profile
    • raxatrigine hydrochloride - Drug Profile
    • RBM-005 - Drug Profile
    • REL-1017 - Drug Profile
    • SAFit2 - Drug Profile
    • Small Molecule for Chronic Pain - Drug Profile
    • Small Molecule for Chronic Pain - Drug Profile
    • Small Molecule for Neuropathic Pain, Chronic Pain and Inflammatory Pain - Drug Profile
    • Small Molecule to Antagonize GPR-84 for Chronic Pain - Drug Profile
    • Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile
    • Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile
    • Small Molecule to Inhibit ASK-1 for Chronic Pain - Drug Profile
    • Small Molecule to Inhibit mPGES-1 for Chronic Pain - Drug Profile
    • Small Molecules for Chronic Wound Pain - Drug Profile
    • Small Molecules to Activate KCNQ2 and KCNQ3 Channels for Chronic Pain and CNS disorder - Drug Profile
    • Small Molecules to Agonize Cannabinoid Type 1 and Type 2 Receptors for Chronic Pain and Neuropathic Pain - Drug Profile
    • Small Molecules to Agonize CB2 for Chronic Pain and Migraine - Drug Profile
    • Small Molecules to Agonize Delta Opioid Receptor for Chronic Pain - Drug Profile
    • Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile
    • Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile
    • Small Molecules to Agonize SSTR4 for Neuropathic Pain and Chronic Pain - Drug Profile
    • Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile
    • Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile
    • Small Molecules to Block Cav2.2 Channel for Chronic Pain - Drug Profile
    • Small Molecules to Block HCN1 Channel for Chronic Neuropathic Pain - Drug Profile
    • Small Molecules to Block Nav 1.7 Channels for Chronic And Neuropathic Pain - Drug Profile
    • Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System - Drug Profile
    • Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain - Drug Profile
    • Small Molecules to Inhibit Cyclooxygenase 2 for Chronic Pain - Drug Profile
    • Small Molecules to Inhibit DAAO for Chronic Pain - Drug Profile
    • Small Molecules to Inhibit Sepiapterin Reductase for Neuropathic and Chronic Pain - Drug Profile
    • Small Molecules to Target Opioid Receptors for Chronic Pain - Drug Profile
    • SYN-003 - Drug Profile
    • Synthetic Peptides to Target Mu Opioid Receptor and Delta Opioid Receptor for Pain - Drug Profile
    • tanezumab - Drug Profile
    • tapentadol hydrochloride IR - Drug Profile
    • TRV-734 - Drug Profile
    • U-2902 - Drug Profile
    • UMB-425 - Drug Profile
    • Vaccine to Target MCP-1 for Chronic Prostatitis and Chronic Pelvic Pain - Drug Profile
    • VM-902A - Drug Profile
    • VYNAV-01 - Drug Profile
    • XT-101 - Drug Profile
    • YYC-301 - Drug Profile
    • ZEP-3 - Drug Profile
    • ZYN-001 - Drug Profile
  • Chronic Pain - Dormant Projects
  • Chronic Pain - Discontinued Products
  • Chronic Pain - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chronic Pain, H2 2016
  • Number of Products under Development for Chronic Pain - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Chronic Pain - Pipeline by AbbVie Inc, H2 2016
  • Chronic Pain - Pipeline by Acadia Pharmaceuticals Inc., H2 2016
  • Chronic Pain - Pipeline by Adynxx, Inc., H2 2016
  • Chronic Pain - Pipeline by Allergan Plc, H2 2016
  • Chronic Pain - Pipeline by Amorsa Therapeutics Inc., H2 2016
  • Chronic Pain - Pipeline by arGEN-X BV, H2 2016
  • Chronic Pain - Pipeline by Asana BioSciences, LLC, H2 2016
  • Chronic Pain - Pipeline by AskAt Inc., H2 2016
  • Chronic Pain - Pipeline by Astraea Therapeutics, LLC, H2 2016
  • Chronic Pain - Pipeline by Axsome Therapeutics, Inc., H2 2016
  • Chronic Pain - Pipeline by BioDelivery Sciences International, Inc., H2 2016
  • Chronic Pain - Pipeline by Biogen Inc, H2 2016
  • Chronic Pain - Pipeline by Bionomics Limited, H2 2016
  • Chronic Pain - Pipeline by Camurus AB, H2 2016
  • Chronic Pain - Pipeline by Cara Therapeutics, Inc., H2 2016
  • Chronic Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016
  • Chronic Pain - Pipeline by ChironWells GmbH, H2 2016
  • Chronic Pain - Pipeline by Collegium Pharmaceutical, Inc., H2 2016
  • Chronic Pain - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016
  • Chronic Pain - Pipeline by Cyclenium Pharma, Inc., H2 2016
  • Chronic Pain - Pipeline by Cytogel Pharma, LLC, H2 2016
  • Chronic Pain - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
  • Chronic Pain - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Chronic Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
  • Chronic Pain - Pipeline by Echo Pharmaceuticals B.V., H2 2016
  • Chronic Pain - Pipeline by Egalet Corporation, H2 2016
  • Chronic Pain - Pipeline by Eli Lilly and Company, H2 2016
  • Chronic Pain - Pipeline by Elite Pharmaceuticals, Inc., H2 2016
  • Chronic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
  • Chronic Pain - Pipeline by Grunenthal GmbH, H2 2016
  • Chronic Pain - Pipeline by Heron Therapeutics, Inc., H2 2016
  • Chronic Pain - Pipeline by INSYS Therapeutics, Inc., H2 2016
  • Chronic Pain - Pipeline by Johnson & Johnson, H2 2016
  • Chronic Pain - Pipeline by Kareus Therapeutics, SA, H2 2016
  • Chronic Pain - Pipeline by KPI Therapeutics, Inc., H2 2016
  • Chronic Pain - Pipeline by Kymab Limited, H2 2016
  • Chronic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016
  • Chronic Pain - Pipeline by Lohocla Research Corporation, H2 2016
  • Chronic Pain - Pipeline by Lpath, Inc., H2 2016
  • Chronic Pain - Pipeline by MD Biosciences GmbH, H2 2016
  • Chronic Pain - Pipeline by Merck & Co., Inc., H2 2016
  • Chronic Pain - Pipeline by Moberg Pharma AB, H2 2016
  • Chronic Pain - Pipeline by Mundipharma International Ltd, H2 2016
  • Chronic Pain - Pipeline by Nanomerics Ltd, H2 2016
  • Chronic Pain - Pipeline by Nektar Therapeutics, H2 2016
  • Chronic Pain - Pipeline by Neura Therapeutik, LLC, H2 2016
  • Chronic Pain - Pipeline by Orion Oyj, H2 2016
  • Chronic Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2016
  • Chronic Pain - Pipeline by Pain Therapeutics, Inc., H2 2016
  • Chronic Pain - Pipeline by PeriphaGen, Inc., H2 2016
  • Chronic Pain - Pipeline by Pfizer Inc., H2 2016
  • Chronic Pain - Pipeline by Phosphagenics Limited, H2 2016
  • Chronic Pain - Pipeline by Prismic Pharmaceuticals, Inc., H2 2016
  • Chronic Pain - Pipeline by Purdue Pharma LP, H2 2016
  • Chronic Pain - Pipeline by Relmada Therapeutics, Inc., H2 2016
  • Chronic Pain - Pipeline by Ribomic Inc., H2 2016
  • Chronic Pain - Pipeline by Sea4Us, H2 2016
  • Chronic Pain - Pipeline by Shulov Innovative Science Ltd., H2 2016
  • Chronic Pain - Pipeline by Synactix Pharmaceuticals, Inc., H2 2016
  • Chronic Pain - Pipeline by Syntrix Biosystems, Inc., H2 2016
  • Chronic Pain - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016
  • Chronic Pain - Pipeline by Therapix Biosciences Ltd., H2 2016
  • Chronic Pain - Pipeline by Trevena, Inc., H2 2016
  • Chronic Pain - Pipeline by Voyager Therapeutics, Inc., H2 2016
  • Chronic Pain - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2016
  • Chronic Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Chronic Pain - Dormant Projects, H2 2016
  • Chronic Pain - Dormant Projects (Contd..1), H2 2016
  • Chronic Pain - Dormant Projects (Contd..2), H2 2016
  • Chronic Pain - Dormant Projects (Contd..3), H2 2016
  • Chronic Pain - Dormant Projects (Contd..4), H2 2016
  • Chronic Pain - Dormant Projects (Contd..5), H2 2016
  • Chronic Pain - Dormant Projects (Contd..6), H2 2016
  • Chronic Pain - Dormant Projects (Contd..7), H2 2016
  • Chronic Pain - Dormant Projects (Contd..8), H2 2016
  • Chronic Pain - Discontinued Products, H2 2016
  • Chronic Pain - Discontinued Products (Contd..1), H2 2016
  • Chronic Pain - Discontinued Products (Contd..2), H2 2016

List of Figures

  • Number of Products under Development for Chronic Pain, H2 2016
  • Number of Products under Development for Chronic Pain - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top